Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease
← catalyst calendarNCT05894343 · readout ≤ 1,168 d
Sponsored by MeiraGTx, LLC (industry) · MGTX — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
13actual
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-19 | actual | When the study began enrolling |
| Primary completion | Oct 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Parkinson's Disease
Intervention
- Genetic: AAV-GAD
Primary outcome
what the primary-completion date above is the date OFNumber of participants with study drug-related adverse events and serious adverse events
measured From study start until Month 60 post treatment
Permalink · MGTX's whole pipeline · Catalyst calendar · Every registered study · What changed